Imaavy (Nipocalimab-Aahu) for Myasthenia Gravis

Overview
Imaavy is approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adults and children aged 12 years and older who test positive for either acetylcholine receptor (AChR) antibodies or muscle-specific tyrosine kinase (MuSK) antibodies. Eligibility for treatment with Imaavy depends on having one of these specific antibody-positive forms of gMG. Imaavy is also known by its drug name, nipocalimab-aahu.

Imaavy is thought to work by reducing levels of harmful immunoglobulin G (IgG) antibodies that disrupt communication between nerves and muscles in people with generalized myasthenia gravis. It blocks the neonatal Fc receptor (FcRn), a protein that normally protects antibodies from being broken down. By interfering with this recycling process, Imaavy helps clear these antibodies from the body more quickly, which may help improve muscle strength over time.

How do I take it?
Prescribing information states that Imaavy is given as an intravenous infusion (into a vein). The initial dose is typically administered over at least 30 minutes. Two weeks later, treatment typically continues with a maintenance dose given every two weeks over at least 15 minutes. The medication should be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Imaavy include respiratory tract infections, peripheral edema (swelling, especially in the legs or hands), and muscle spasms.

Rare but serious side effects may include severe infections, hypersensitivity reactions such as angioedema (swelling under the skin), anaphylaxis (a life-threatening allergic reaction), rash, hives (urticaria), and eczema (a skin condition causing discoloration and itching). Severe infusion-related reactions may also occur and require stopping treatment. Mild or moderate infusion reactions may allow for continued treatment with precautions.

For more information about this treatment, visit:
Imaavytm (Nipocalimab-Aahu) Injection, for Intravenous Use — Janssen Biotech